Across TCGA pan-cancer cohorts, MIR425 RNA is linked to patient survival in 11 of 34 cancer types, making it the most broadly survival-associated MIR425 data layer.
The strongest signal is observed in thyroid carcinoma (THCA), where higher MIR425 RNA is associated with worse disease-free survival. In most high-consensus cancer types, elevated MIR425 expression acts as an unfavorable survival marker, although some lineages such as STAD show a favorable association.
THCA, COAD, and STAD are the cancer types where MIR425 RNA most reproducibly stratifies survival.
RNA survival associations by lineage
Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.